On December 15, 2023 Prof. Dr. Giuseppe Curigliano, on behalf of Philogen, reported that he will be giving a presentation about the Phase I DODEKA study on February 26th, entitled "Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors" (Press release, Philogen, DEC 15, 2023, https://www.philogen.com/2023/12/15/philogen-to-attend-the-esmo-tat-congress-in-paris-on-february-26-28-2024/ [SID1234638615]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Jacqueline Mock will be presenting a poster about Philochem’s new small molecule drug conjugate on February 26th, entitled "Optimisation of FAP-targeted small molecule drug conjugates for the delivery and release of cytotoxic payloads in solid tumors"